{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:35:39Z","timestamp":1793205339042,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":3415,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1038\/sj.ki.5001580","type":"journal-article","created":{"date-parts":[[2006,6,14]],"date-time":"2006-06-14T13:49:55Z","timestamp":1150292995000},"page":"536-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":179,"title":["Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy"],"prefix":"10.1016","volume":"70","author":[{"given":"K.J.","family":"Schjoedt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.R.","family":"Juhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Boomsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Tarnow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.H.","family":"Parving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/sj.ki.5001580_bb0010","series-title":"The Kidney","first-page":"1777","article-title":"Diabetic nephropathy","author":"Parving","year":"2004"},{"key":"10.1038\/sj.ki.5001580_bb0015","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/bmj.299.6693.230","article-title":"Prognosis in diabetic nephropathy","volume":"299","author":"Parving","year":"1989","journal-title":"BMJ"},{"key":"10.1038\/sj.ki.5001580_bb0020","first-page":"437","article-title":"The natural history of diabetic renal disease. A follow-up study of series of renal biopsies","volume":"41","author":"Watkins","year":"1972","journal-title":"Q J Med"},{"key":"10.1038\/sj.ki.5001580_bb0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s001250050140","article-title":"Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment","volume":"37","author":"Rossing","year":"1994","journal-title":"Diabetologia"},{"key":"10.1038\/sj.ki.5001580_bb0030","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001580_bb0035","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5001580_bb0040","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/ki.1994.469","article-title":"Remission of nephrotic-range proteinuria in type I diabetes","volume":"46","author":"Hebert","year":"1994","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001580_bb0045","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.2337\/diacare.24.11.1972","article-title":"Remission of nephrotic-range albuminuria in type 1 diabetic patients","volume":"24","author":"Hovind","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1038\/sj.ki.5001580_bb0050","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1523-1755.2004.00870.x","article-title":"Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy","volume":"66","author":"Hovind","year":"2004","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001580_bb0055","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s00125-005-1937-6","article-title":"Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients","volume":"48","author":"Rossing","year":"2005","journal-title":"Diabetologia"},{"key":"10.1038\/sj.ki.5001580_bb0060","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001580_bb0065","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1038\/sj.ki.5001580_bb0070","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabet Med"},{"key":"10.1038\/sj.ki.5001580_bb0075","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1038\/sj.ki.5001580_bb0080","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/01.ASN.0000054495.96193.BF","article-title":"Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy","volume":"14","author":"Jacobsen","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/sj.ki.5001580_bb0085","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1523-1755.2000.00880.x","article-title":"Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy","volume":"57","author":"Andersen","year":"2000","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001580_bb0090","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","article-title":"Dual blockade of the renin\u2013angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy","volume":"63","author":"Jacobsen","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001580_bb0095","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.2337\/diacare.26.8.2268","article-title":"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1038\/sj.ki.5001580_bb0100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ndt\/18.2.293","article-title":"Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy","volume":"18","author":"Andersen","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/sj.ki.5001580_bb0105","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/ndt\/16.4.771","article-title":"Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM","volume":"16","author":"Buter","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/sj.ki.5001580_bb0110","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001580_bb0115","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001580_bb0120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/sj.ki.5001580_bb0125","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.HYP.0000154082.72286.2a","article-title":"Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study","volume":"45","author":"Ibsen","year":"2005","journal-title":"Hypertension"},{"key":"10.1038\/sj.ki.5001580_bb0130","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1111\/j.1523-1755.2004.09226.x","article-title":"Beneficial impact on cardiovascular risk factors by dual blockade of the renin\u2013angiotensin system in diabetic nephropathy","volume":"66","author":"Jacobsen","year":"2004","journal-title":"Kidney Int Suppl"},{"key":"10.1038\/sj.ki.5001580_bb0135","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/01.CIR.0000047526.08376.80","article-title":"Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies","volume":"107","author":"Ruggenenti","year":"2003","journal-title":"Circulation"},{"key":"10.1038\/sj.ki.5001580_bb0140","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1038\/sj.ki.5001580_bb0145","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES])","volume":"78","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1038\/sj.ki.5001580_bb0150","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin\u2013angiotensin\u2013aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1038\/sj.ki.5001580_bb0155","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/ki.1992.118","article-title":"Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients","volume":"41","author":"Parving","year":"1992","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001580_bb0160","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM199611283352212","article-title":"Initiation and progression of diabetic nephropathy","volume":"335","author":"Parving","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.ki.5001580_bb0165","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0272-6386(01)80115-3","article-title":"Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications","volume":"37","author":"Epstein","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/sj.ki.5001580_bb0170","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1038\/sj.ki.5001580_bb0175","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"Blasi","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/sj.ki.5001580_bb0180","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/S0735-1097(01)01237-2","article-title":"Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype","volume":"37","author":"Cicoira","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/sj.ki.5001580_bb0185","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(83)92462-5","article-title":"Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy","volume":"i","author":"Parving","year":"1983","journal-title":"Lancet"},{"key":"10.1038\/sj.ki.5001580_bb0190","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1136\/bmj.316.7146.1719","article-title":"Understanding controlled trials. Crossover trials","volume":"316","author":"Sibbald","year":"1998","journal-title":"BMJ"},{"key":"10.1038\/sj.ki.5001580_bb0195","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/00365517609068016","article-title":"Selection of routine method for determination of glomerular filtration rate in adult patients","volume":"36","author":"Br\u00f6chner-Mortensen","year":"1976","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1038\/sj.ki.5001580_bb0200","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/00365517209084290","article-title":"A simple method for the determination of glomerular filtration rate","volume":"30","author":"Br\u00f6chner-Mortensen","year":"1972","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1038\/sj.ki.5001580_bb0205","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/01.HYP.5.2.244","article-title":"Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis","volume":"5","author":"Derkx","year":"1983","journal-title":"Hypertension"},{"key":"10.1038\/sj.ki.5001580_bb0210","series-title":"Practical Statistics for Medical Research","first-page":"440","article-title":"Clinical trials","author":"Altman","year":"1991"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815519674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815519674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T10:03:45Z","timestamp":1668593025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815519674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0085253815519674"],"URL":"https:\/\/doi.org\/10.1038\/sj.ki.5001580","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/sj.ki.5001580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}